TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22228415

Group type: EXPERIMENTAL
Intervention: CsA/Aza
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Tac/MMF
Number of subjects: 289
Study: 19158589

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Activity diary
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pedometer and Activity diary comparison
Number of subjects: 80
Study: 17134960

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day) combined with diet
Number of subjects: 139

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 139
Study: 16260202

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVU)
Number of subjects: 39115

Group type: EXPERIMENTAL
Intervention: CA‐125
Number of subjects: 39115

Group type: EXPERIMENTAL
Intervention: Both tests (TVU and CA‐125)
Number of subjects: 39115

Group type: EXPERIMENTAL
Intervention: TVU
Number of subjects: 39115

Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 39115
Study: 11868008

Group type: EXPERIMENTAL
Intervention: Tannenbaum stent
Number of subjects: 106

Group type: COMPARATOR
Intervention: Polyethylene stent
Number of subjects: 106
Study: 10506815

Group type: EXPERIMENTAL
Intervention: KeraVision Intacs
Number of subjects: 95
Study: 7603372

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 160000

Group type: COMPARATOR
Intervention: Control group (no mammographic screening)
Number of subjects: 160000
Study: 2088995

Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine (MS Contin Tablets; MSC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Previous analgesic regimens
Number of subjects: 70
Study: 7206385

Group type: EXPERIMENTAL
Intervention: Stress condition (S group) with negative and stressful comments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonstress condition (NS group) with positive and comfortable comments
Number of subjects: 30
Study: 31813658

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) monotherapy for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) monotherapy
Number of subjects: 26
Study: 28560502

Group type: EXPERIMENTAL
Intervention: Infiltration treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 27604241

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 53
Study: 24912053

Group type: EXPERIMENTAL
Intervention: Strawberry consumption (500 g daily for 30 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 31
Study: 22360383

Group type: EXPERIMENTAL
Intervention: Sildenafil (thrice daily for 4 weeks)
Number of subjects: 10
Study: 20105143

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment during infancy and childhood
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 37
Study: 18767582

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongji (CV 3), Shuidao (ST 28), Tainshu (ST 25), Qugu (CV 2), Zigong (EX-CA 1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral administration of Danazol (medication group)
Number of subjects: 66
Study: 15933482

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting risperidone (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (50-week study)
Number of subjects: 0
Study: 12870776

Group type: EXPERIMENTAL
Intervention: Guar gum (9 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (50 g glucose without guar)
Number of subjects: 11
Study: 10554499

Group type: EXPERIMENTAL
Intervention: Bolus group (15 micrograms.kg‐1 bolus dose + 0.1 microgram.kg‐1.min‐1 infusion, n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-bolus group (0.1 microgram.kg‐1.min‐1 infusion, n = 8)
Number of subjects: 17
Study: 8686675

Group type: EXPERIMENTAL
Intervention: TRD-B (tongue retaining device with anterior bulb)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TRD-A (tongue retaining device without anterior bulb)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TRD-A
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TRD-X (tongue resting outside anterior bulb)
Number of subjects: 16
Study: 1878533

Group type: EXPERIMENTAL
Intervention: GMS-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GMS-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 6847336

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 15 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31167875

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (reference) after PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (reference) after CABG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAPT plus an anticoagulant (Triple Therapy)
Number of subjects: 0
Study: 30239243

Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 26944692

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) health coaching in addition to usual care
Number of subjects: 668

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 668
Study: 24485480

Group type: EXPERIMENTAL
Intervention: Standardized psychosocial laboratory stressor (the Trier Social Stress Test for Children)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control condition without exposure to socio‐evaluative stress
Number of subjects: 39
Study: 22075192

Group type: EXPERIMENTAL
Intervention: Guidewire (GW) cannulation
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Contrast injection (ConI)
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Low-risk patients
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Unintended MPD cannulation or opacification with GW
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Unintended MPD cannulation or opacification with ConI
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Manipulation of the MPD
Number of subjects: 1249
Study: 20854343

Group type: EXPERIMENTAL
Intervention: Admission Service (AS)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Standard admission process
Number of subjects: 314
Study: 17932353

Group type: EXPERIMENTAL
Intervention: Scripted telephone support provided by a Prevention Care Manager (PCM)
Number of subjects: 1346
Study: 15939927

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Routine medical care (Control)
Number of subjects: 155
Study: 12495391

Group type: COMPARATOR
Intervention: VVI‐40 (ventricular backup pacing at 40/min; n = 256)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: DDDR‐70 (dual‐chamber rate‐responsive pacing at 70/min; n = 250)
Number of subjects: 506

Group type: COMPARATOR
Intervention: VVI‐40
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: DDDR‐70
Number of subjects: 506
Study: 9661644

Group type: EXPERIMENTAL
Intervention: 500 mg metformin, x 3 daily for 2 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 500 mg metformin, x 3 daily for 4-6 months (in 12 women)
Number of subjects: 26
Study: 7631730

Group type: EXPERIMENTAL
Intervention: Active pelvic floor stimulator
Number of subjects: 52
Study: 2739017

Group type: EXPERIMENTAL
Intervention: 100% oxygen during recovery period
Number of subjects: 12

Group type: COMPARATOR
Intervention: room air during recovery period
Number of subjects: 12
Study: 31438896

Group type: EXPERIMENTAL
Intervention: Solar Suitcase
Number of subjects: 30
Study: 28235705

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered immediately prior to the stressor
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered 10 minutes prior to the stressor
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge administered prior to the stressor
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nicotine lozenge administered after the stressor
Number of subjects: 84
Study: 25906190

Group type: EXPERIMENTAL
Intervention: PKA‐BIS protocol (combined propofol and ketamine hydrochloride anesthesia with bispectral index monitoring)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PKA‐BIS protocol
Number of subjects: 30
Study: 22930256

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (rituximab and azathioprine)
Number of subjects: 7
Study: 16547531

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers with vasodilatory properties
Number of subjects: 0
Study: 12867587

Group type: EXPERIMENTAL
Intervention: 120 mg methylprednisolone acetate (MPA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10619792

Group type: EXPERIMENTAL
Intervention: High-dose CPB chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) and peripheral blood progenitor cell support (PBPCS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard-dose CPB chemotherapy (SDC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Induction CAF chemotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prednisone treatment for DPTS
Number of subjects: 150
Study: 8926668

Group type: EXPERIMENTAL
Intervention: Double-cross plasty with preservation of tunics and placement of their edges under the back muscles
Number of subjects: 115

Group type: COMPARATOR
Intervention: Muscular-fascial plasty
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Double-cross plasty
Number of subjects: 115
Study: 1629142

Group type: EXPERIMENTAL
Intervention: Enalapril (5-20 mg daily, mean dose 7.2 mg)
Number of subjects: 30
Study: 6091248

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (100 micrograms i.m. daily for 15 days during 6 consecutive months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo injections)
Number of subjects: 20
Study: 31200638

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (1 mg bolus over 30 min followed by 2 μg/kg/h continuous infusion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion and Control (normal saline)
Number of subjects: 50
Study: 28729617

Group type: EXPERIMENTAL
Intervention: Active electrical stimulation (ES) of the calf muscles
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham electrical stimulation (ES) of the calf muscles
Number of subjects: 13
Study: 25840790

Group type: EXPERIMENTAL
Intervention: TWG technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: CS technique
Number of subjects: 80
Study: 23489466

Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine (0.5%)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 3
Study: 20808113

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms (IS) assessment through standardized questionnaires
Number of subjects: 5846

Group type: EXPERIMENTAL
Intervention: Multivariate regression analyses stratified by gender
Number of subjects: 5846

Group type: EXPERIMENTAL
Intervention: Age as a factor in insomnia symptoms
Number of subjects: 5846

Group type: EXPERIMENTAL
Intervention: Loud snoring as a factor in insomnia symptoms
Number of subjects: 5846

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) as a factor in insomnia symptoms
Number of subjects: 5846

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy, Mediterranean diet, caffeine and alcohol intake as protective factors
Number of subjects: 5846
Study: 19331578

Group type: EXPERIMENTAL
Intervention: 10(6)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sexually active participants engaging in sexual intercourse with condoms
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sexually active participants having unprotected sex
Number of subjects: 90
Study: 17342295

Group type: EXPERIMENTAL
Intervention: 80 mg Depo-Medrol
Number of subjects: 84

Group type: COMPARATOR
Intervention: 40 mg Depo-Medrol
Number of subjects: 84
Study: 14761108

Group type: EXPERIMENTAL
Intervention: Provider-completed ALPHA form
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Self-reported ALPHA form
Number of subjects: 76

Group type: COMPARATOR
Intervention: Provider type (Physicians vs. PHNs)
Number of subjects: 76
Study: 11672948

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg bodyweight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 50
Study: 9626212

Group type: EXPERIMENTAL
Intervention: CODE (cisplatin, vincristine, doxorubicin, etoposide + G-CSF)
Number of subjects: 227

Group type: COMPARATOR
Intervention: CAV/PE (cyclophosphamide, doxorubicin, vincristine, cisplatin, etoposide)
Number of subjects: 227
Study: 7842516

Group type: EXPERIMENTAL
Intervention: 0.2125 M sucrose
Number of subjects: 2

Group type: COMPARATOR
Intervention: Water
Number of subjects: 2
Study: 3339217

Group type: EXPERIMENTAL
Intervention: 16-week exercise program (3 hours/week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 35
Study: 31645430

Group type: EXPERIMENTAL
Intervention: Maternal ART
Number of subjects: 76
Study: 28665340

Group type: EXPERIMENTAL
Intervention: Therapy dog (TD) exposure (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No-dog control (C) (n = 30)
Number of subjects: 61
Study: 25229260

Group type: EXPERIMENTAL
Intervention: Early exercise regime (5‐6 times for 45 minutes during and after radiotherapy supervised by a physiotherapist)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study: 23243082

Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron once weekly (group A)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 12.5 mg elemental iron once daily (group B)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 0.5 ml of a natural color additive (control group C)
Number of subjects: 210
Study: 21676056

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 50
Study: 17960589

Group type: EXPERIMENTAL
Intervention: Conventional therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-learning program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual or no therapy (Control)
Number of subjects: 0
Study: 16495730

Group type: EXPERIMENTAL
Intervention: Tc‐99m EC scintigraphy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tc‐99m DMSA scintigraphy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Comparison of DRF
Number of subjects: 62
Study: 15598063

Group type: EXPERIMENTAL
Intervention: Community-based pharmaceutical care for the elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10866043

Group type: EXPERIMENTAL
Intervention: Intravenous and/or subcutaneous insulin in 29 patients with newly diagnosed type 1 diabetes
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin prophylaxis in 14 islet cell antibody-positive relatives
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) plus subcutaneous insulin in 10 newly diagnosed patients
Number of subjects: 53
Study: 9349929

Group type: EXPERIMENTAL
Intervention: Turbuhaler (1.2 mg salbutamol, 12 x 100 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diskus (1.2 mg salbutamol, 6 x 200 micrograms)
Number of subjects: 8
Study: 1439642

Group type: EXPERIMENTAL
Intervention: Suture closure (interrupted sutures of 000 polyester)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Stapling closure (autosuture stapler)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 304

Group type: COMPARATOR
Intervention: Stapling closure
Number of subjects: 304
Study: 2991486

Group type: EXPERIMENTAL
Intervention: PCV (procarbazine, CCNU, and vincristine)
Number of subjects: 148

Group type: COMPARATOR
Intervention: BCNU (1,3‐bis(2‐chloroethyl)‐1‐nitrosourea)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 148

Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 148
Study: 30740936

Group type: EXPERIMENTAL
Intervention: Laser dissection mass spectrometry (LDMS)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Congo red (CR) staining followed by immunohistochemistry (IHC)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: LDMS
Number of subjects: 640
Study: 29406451

Group type: EXPERIMENTAL
Intervention: Psychological workbook (LEARN technique and goal setting)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Information-only workbook (control)
Number of subjects: 139
Study: 27352955

Group type: EXPERIMENTAL
Intervention: High adherence (≥80% medication adherence)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Low adherence (<80% medication adherence)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 699
Study: 24659797

Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Ponesimod
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 22976260

Group type: EXPERIMENTAL
Intervention: Achillea millefolium (1.5 g powdered flower, 3 days a week for 2 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 20200346

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 18034664

Group type: EXPERIMENTAL
Intervention: Active knowledge transfer (knowledge brokers visiting every 2 months for 1 year, 2 hours per visit)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Passive knowledge transfer (evidence-based knowledge material available on Internet every week for 1 year)
Number of subjects: 72
Study: 15618787

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 90
Study: 12394379

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10 colony-forming units daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (comparable to GG)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 220

Group type: COMPARATOR
Intervention: Non-breast-fed
Number of subjects: 220
Study: 10480513

Group type: EXPERIMENTAL
Intervention: Diabetic enrollees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondiabetic enrollees
Number of subjects: 0
Study: 8628880

Group type: EXPERIMENTAL
Intervention: 3D stereotaxic surface projection (SSP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard transaxial display
Number of subjects: 39
Study: 1960663

Group type: EXPERIMENTAL
Intervention: Formaldehyde-tyrothricin solution placed in periodontal pockets
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo solution placed in periodontal pockets (Control)
Number of subjects: 14
Study: 6452797

Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zimelidine 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31851385

Group type: EXPERIMENTAL
Intervention: Tailored and dose-dense (DD) epirubicin and cyclophosphamide followed by docetaxel + 1 year of adjuvant trastuzumab
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard 5-fluorouracil, epirubicin, and cyclophosphamide plus docetaxel every 3 weeks + 1 year of adjuvant trastuzumab
Number of subjects: 342
Study: 29859132

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 14
Study: 29146647

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (NOT) consisting of intravenous antibiotics for 48-72 hours, daily blood tests, and ultrasound follow-up, followed by oral antibiotics if discharge criteria are met.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (NOT)
Number of subjects: 334
Study: 25269991

Group type: EXPERIMENTAL
Intervention: 8% arginine and calcium carbonate desensitizing paste (test group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoride-free prophylaxis paste (control group)
Number of subjects: 50
Study: 23697466

Group type: EXPERIMENTAL
Intervention: Placebo drink (presumed effective antiemetic)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no drink)
Number of subjects: 96
Study: 22003000

Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC) at doses above 1.00 mg/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 18069698

Group type: COMPARATOR
Intervention: Standard treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for 48 weeks
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Variable treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for individualized duration based on HCV RNA negativity at weeks 4, 8, or 12
Number of subjects: 696

Group type: COMPARATOR
Intervention: Standard treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Variable treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Treatment duration of 48 weeks versus 24 weeks for RVR patients with baseline viremia >or=400,000 IU/mL
Number of subjects: 696